The submission is based on a phase II/III U.S. study of the messenger RNA (mRNA) vaccine, mRNA-1273, in 2,500 participants ages 12 to younger than 18. Efficacy in 2,500 adolescents who received the Moderna COVID-19 vaccine was 100% when using the same case definition as in a phase III study in adults. In addition, a vaccine efficacy of 93% in seronegative participants was observed starting 14 days after the first dose, according to the company.

The Moderna COVID-19 vaccine was generally well tolerated, with a safety and tolerability profile generally consistent with the phase III study evaluated for EUA in adults. No significant safety concerns have been identified to date, Moderna said.

The company said it has already filed for authorization with Health Canada and the European Medicines Agency and will file with regulatory agencies around the world for the younger age population.

Moderna, Medison partner on Moderna's COVID-19 vaccine
Moderna and Medison Pharma announced that they are entering into a marketing agreement for Moderna's COVID-19 vaccine across central Europe and Israel.

Moderna initiates rolling BLA for COVID-19 vaccine
Moderna has started the rolling submission process with the U.S. Food and Drug Administration for a biologics license application (BLA) for the use of...

Thermo, Moderna ink COVID-19 vaccine manufacturing deal
Moderna has signed a deal with Thermo Fisher Scientific to provide manufacturing services and supply packaging for its COVID-19 vaccine.

Moderna vaccine 100% effective for teens
Moderna announced its phase II/III study of its COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint with no cases of COVID-19...

Moderna inks South Korean mRNA vaccine collaborations
Moderna has inked two memoranda of understanding agreements with South Korea for messenger RNA (mRNA) vaccine research and manufacturing in that country.